Skip to ContentSkip to Navigation
University of Groningenfounded in 1614  -  top 100 university
About us Practical matters How to find us dr. A.J. van der Wekken
University Medical Center Groningen

dr. A.J. van der Wekken

pulmonary oncologist
Profile picture of dr. A.J. van der Wekken
E-mail:
a.j.van.der.wekken umcg.nl

Publications

A Drug–Drug Interaction Study of Mobocertinib and Midazolam, a Cytochrome P450 3A Substrate, in Patients With Advanced Non–Small Cell Lung Cancer

Circulating Tumor DNA in Advanced EGFRex20+ NSCLC: Concordance with Tissue Biopsy, Monitoring of Response, and Resistance to High-Dose Osimertinib

Detection of actionable mutations in circulating tumor DNA for non-small cell lung cancer patients

Molecular determinants of sotorasib clinical efficacy in KRASG12C-mutated non-small-cell lung cancer

Opportunities for Precision Dosing of Cytotoxic Drugs in Non-Small Cell Lung Cancer: Bridging the Gap in Precision Medicine

Pooled safety analysis and management of sotorasib-related adverse events in KRAS G12C-mutated advanced non-small cell lung cancer

Presence of On-Target Resistant Mutation in Pre-Treatment Samples of ALK Fusion Gene Positive Lung Cancer Patients

Sex and Common Germline Variants Affect the Toxicity Profile and Pharmacokinetics of Alectinib: A Nationwide Cohort Study in Patients With ALK-Positive NSCLC

Sotorasib versus docetaxel for previously treated KRAS G12C–mutated non–small–cell lung cancer: a plain language summary

Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case Series

Press/media

Longkanker is altijd pech

Door chemotekorten worden minder effectieve behandelingen ingezet

Stand van Nederland - Wereld op Scherp: Een bittere pil (WNL NPO2)

Zorgen bij ziekenhuizen over tekorten aan middelen voor chemokuren

RTV Noord Vandaag

Effect van pil tegen longkanker

Pil tegen longkanker 'halveert kans op overlijden' voor kleine groep patiënten

Hoop voor kleine groep longkankerpatiënten: pil per dag halveert kans op overlijden

Doelgerichte therapie bij longkanker